Business
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced
About this update from Fortress Biotech, Inc.
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/neErxfmHzpck8XzIhTCP2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mg--/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/neErxfmHzpck8XzIhTCP2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mg--/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026","length":138,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi™, with expanded payer access anticipated to facilitate further growth in total prescription demand. ","length":881,"tagName":"p"},{"type":"text","content":"“We are extremely pleased with the completion of this milestone for Emrosi™,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Our focus on delivering cost-effective access to high-quality dermatology therapies is expected to expand coverage and improve patient access, positioning Emrosi™ for sustained commercial growth. Now that our contracts have been secured with the three major GPOs, we look forward to continuing to increase coverage f...